Tradestie Institutional Equity Comparison Engine
GNPX vs REGN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
REGN Overall Edge
REGN Captures Institutional Edge (4โ0 Pillars ยท 10โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Regeneron Pharmaceuticals Inc (REGN) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, GNPX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus REGN at 14.8x Forward P/E and 30.4% operating margin (+36.3% YoY). In options structure, GNPX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against REGN sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
REGN
GNPX N/M vs REGN 14.8x Fwd P/E
Growth & Margin Winner
REGN
Op Margin 0.0% vs 30.4% ยท YoY +0.0% vs +36.3%
Momentum & Technical Winner
REGN
1Y -56.6% vs +31.0% ยท 52W Pos 11% vs 82%
Options & Structure Winner
REGN
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (6th %ile IV)
GNPX
NASDAQ
Genprex, Inc. Common Stock
Pharmaceutical Preparations
$1.45
-13.17% 1D
Market Cap
$2.2M
1M Return
-26.77%
1Y Return
-56.59%
Forward P/E
N/M
Unified AI Score
42.2 / 100
HOLD
Tech 25.0
Fund 47.0
Flow 50.0
Mom 59.0
REGN
NASDAQ
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$920.69
-0.29% 1D
Market Cap
$95.5B
1M Return
+12.4%
1Y Return
+31.01%
Forward P/E
14.8x
Unified AI Score
46.0 / 100
HOLD
Tech 29.0
Fund 49.0
Flow 69.0
Mom 56.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
GNPX -56.59%
REGN +31.01%
Spread: +87.6 pp (REGN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
GNPX TTM Op. Margin: 0.0%
REGN TTM Op. Margin: 30.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GNPX vs REGN. Trailing 12-month operating profitability (GNPX 0.0% vs REGN 30.4%) and valuation multiples (GNPX N/M vs REGN 14.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | GNPX | REGN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.2M | $95.5B | Larger Scale | REGN |
| Trailing P/E Ratio Valuation | N/M | 20.4x | Lower Multiple | REGN |
| Forward P/E Ratio Valuation | N/M | 14.8x | Lower Multiple | REGN |
| Revenue Growth (YoY) Growth | +0.0% | +36.3% | Higher Growth | REGN |
| Operating Margin (TTM) Profitability | 0.0% | 30.4% | Higher Margin | REGN |
| Net Profit Margin Profitability | 0.0% | 28.5% | Higher Margin | REGN |
| Return on Equity (ROE) Capital Efficiency | -233.7% | 14.9% | Higher ROE | REGN |
| 52-Week Range Position Momentum | 11% ($0โ$10) | 82% ($592โ$992) | Stronger Trend | REGN |
| Beta / 30D Volatility Risk Regime | -4.68ฮฒ ยท 96% Vol | 0.30ฮฒ ยท 55% Vol | Lower Realized Risk | REGN |
| Unified Institutional Score Composite Signal | 42.2 / 100 (HOLD) | 46.0 / 100 (HOLD) | Higher Composite | REGN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full GNPX vs REGN Buy Guide
GNPX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
REGN
CONSOLIDATION
56d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
6th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither GNPX nor REGN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.